INS and type 2 diabetes mellitus: Although this is a modest decrease for people with T2D, it is similar to that observed in the DPP trial, which had clinically meaningful reductions in T2D risk.5 Similar to prior trials11,13 in individuals with and without T2D, the intervention led to a 6-month decrease in body weight, waist circumference, fasting insulin, and HOMA-IR.